This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Jiang, M.-s. Articles by Hart, G. W. Search for Related Content PubMed PubMed Citation Articles by Jiang, M.-s. Articles by Hart, G. W.

Adrenal Carcinoma Tumor Progression and Penultimate Cell Surface Oligosaccharides¹

Department of Biological Chemistry [M-s. J., G. W. H.] and Department of Medicine [M. B. P.], The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 and Gerontology Research Center, National Institutes on Aging, Baltimore, Maryland 21224 [A. P.]

Many previous studies have implicated cell surface saccharides, and sialylglycoconjugates in particular, as important mediators of tumor cell metastasis. In this report, we have used three different specific sialidases and a highly sensitive high-performance liquid chromatographic sialic acid assay to probe the cell surfaces of several murine adrenal carcinoma variants. In contrast to several earlier studies on other metastatic variants, we find no significant differences in the overall levels of cell surface or total cellular sialic acid among three Y1 murine adrenal carcinoma variants with widely different metastatic phenotypes. However, using highly purified, linkage-specific sialyltransferases, in conjunction with V. cholerae sialidase, to probe the cell surface saccharide topography of specific penultimate oligosaccharides, we do find striking differences in oligosaccharide structures underlying the sialic acid moieties. Two tumorigenic and metastatic variants (F2 and F4) contain about 6-fold more penultimate Galß14GlcNAc sialylation sites than a related tumorigenic but nonmetastatic variant (HSR) when CMP-[³H]-N-acetylneuraminic acid and the Galß14GlcNAc 2,6 sialyltransferase are used to probe the adrenal carcinoma cell surfaces. The metastatic variants also are found to contain 4- to 4.5-fold more Galß13GalNAc sialylation sites than the nonmetastatic variant when the Galß13GalNAc 2,3 sialyltransferase is used as a cell surface probe. Earlier work, which used the same sialyltransferase probes on sialidase-treated murine melanoma variants (A. Passaniti and G. W. Hart, J. Biol. Chem., 263: 7591–7603, 1988), also showed similar quantitative differences in penultimate structures between metastatic variants. However, in contrast to the adrenal carcinoma cells, the highly metastatic melanoma cells have severalfold lower levels of sialylatable penultimate Galß14GlcNAc and Galß13GalNAc saccharides compared to their nonmetastatic counterparts. Thus, while the precise structural alterations or surface accessibilities of penultimate saccharides appear to be cell type dependent, these results suggest that pronounced changes in penultimate cell surface sialo-oligosaccharide moieties occur during progression to a malignant phenotype in two widely different tumor systems. These types of alterations in the underlying penultimate oligosaccharide structures of cell surface sialoglycoconjugates may be a common feature of highly metastatic cells arising from very different tumor cell types.

¹ This work was supported by NIH Grant CA42486 from the National Cancer Institute.

² To whom requests for reprints should be addressed, at Department of Biological Chemistry, The Johns Hopkins University School of Medicine, 725 N. Wolfe Street, Baltimore, MD 21205.

Received 8/28/91. Accepted 2/10/92.